Please feel free to offer comments and raise questions in our Discussion Forums.

Transcript

Download PDF Transcript

Transcript

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?".  Our

Here's part 1 of the podcast with Dr. Ramaswamy Govindan from Washington University, in St. Louis, and Dr. Julie Brahmer from Johns Hopkins University in Baltimore, splitting the big topic of new developments in immunotherapy for lung cancer.

This is the last of six podcasts produced from the two hour program we did in partnership with the LUNGevity Foundation earlier this year in Santa Monica, at the start of the "Targeted Therapies in Lung Cancer" annual meeting.  This activity was comprised of some great panel discussions and brief presentations on tough but timely issues on the subject of "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?".  It featured guest faculty members Dr. Charlie Rudin from Johns Hopkins University, Dr. Alice Shaw from Massachusetts General Hospital, Dr.

Here's part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity.  In this podcast, my friend Dr.

Here's the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David Spigel, and Glen Goss.  We continued our animated discussion on the promise as well as the pitfalls of broadening the use of molecular markers in routine practice of managing patients with advanced NSCLC.

I'm happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?", in which I was joined by Drs.